Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Encouraging results from Recce Pharmaceuticals in fight against drug resistant bacteria
    • News

    Encouraging results from Recce Pharmaceuticals in fight against drug resistant bacteria

    As the world prepares for a myriad of drug-resistant bacteria following decades of over-prescribing and improper use of antibiotics, Recce Pharmaceuticals (ASX: RCE) has reported encouraging clinical results in response to multi drug resistant bacterial sinusitis infection. Following on from promising results observed in animal studies, a 59-year-old male was treated with the compound R327

    Read More
    Public
  • No international students, no problem – iCollege records record revenue
    • News

    No international students, no problem – iCollege records record revenue

    Despite the travel restrictions that have limited international student enrollments in Australia, domestic students have used the opportunity to hone their skill sets with education provider iCollege (ASX: ICT) recording record revenue for the March quarter.  Revenue for the quarter was up 52% to $4.55 million compared to the previous corresponding quarter ($2.99m) when the

    Read More
    Public
  • Crowd Media showcases newest AI as example of disruption to eCommerce
    • News

    Crowd Media showcases newest AI as example of disruption to eCommerce

    Online shopping experiences will soon be very different to the current one-dimensional standard following the launch of artificial intelligence company Crowd Media’s (ASX: CM8) latest talking head which was produced entirely by digital media and powered by AI.  The talking head named ‘Digital Dom’ is a digital avatar of Crowd’s co-founder and Director Domenic Carosa

    Read More
    Public
  • Investor loads up on aspirin in response to COVID vaccine side effects
    • Satire

    Investor loads up on aspirin in response to COVID vaccine side effects

    Amid news of the COVID-19 vaccine leading to blood clotting as a side effect among recipients, investor Hugh Honey has identified an investment opportunity whereby he has emptied the shelves of supermarkets and pharmacies across the country, hoarding all the aspirin he can get his hands on.  Honey, a long time aspirin user, drew upon

    Read More
    Public
  • Australia’s China Hustle
    • Opinion

    Australia’s China Hustle

    Several large Chinese operations have listed on the ASX across the past five years, usually with impressive financials and promises of strong, consistent, future growth. These companies have always been attractively priced and always seemed to report extremely well. What was the problem? Well, put simply, some of these companies may not exist at all,

    Read More
    Public
  • Here’s cheers: the craft beer market offers plenty of upside to the discerning operators
    • Opinion

    Here’s cheers: the craft beer market offers plenty of upside to the discerning operators

    Investors thirsting for an ASX beer exposure have been left largely unsated since Fosters/Carlton United Breweries and Lion Nathan were subsumed by foreign buyers a few years back. Coca Cola Amatil (CCL) has long held beer and spirits ambitions that have never quite come to fruition, but in any event the bottler looks headed to

    Read More
    Public
  • «
  • ‹
  • 515
  • 516
  • 517
  • 518
  • 519
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.